These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33068291)

  • 1. Catastrophic Hemorrhage After Chemoradiation for Advanced Stage Oropharyngeal Carcinoma: A Case Series.
    Chou CT; Rath TJ; Johnson JT; Goyal LK
    Laryngoscope; 2021 May; 131(5):1049-1052. PubMed ID: 33068291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
    Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
    Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a chemoradiation therapy toxicity staging system for oropharyngeal carcinoma.
    Goepfert RP; Yom SS; Ryan WR; Cheung SW
    Laryngoscope; 2015 Apr; 125(4):869-76. PubMed ID: 25388529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma.
    Self EM; Bumpous J; Ziegler C; Wilson L; Potts K
    JAMA Otolaryngol Head Neck Surg; 2013 Apr; 139(4):356-61. PubMed ID: 23599070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major haemorrhage after non-surgical management of oropharyngeal squamous cell carcinoma.
    Leedman S; Thompson A; Phillips T; Sader C
    J Laryngol Otol; 2023 Jun; 137(6):667-672. PubMed ID: 35979640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.
    Beitler JJ; Quon H; Jones CU; Salama JK; Busse PM; Cooper JS; Koyfman SA; Ridge JA; Saba NF; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS;
    Head Neck; 2016 Sep; 38(9):1299-309. PubMed ID: 27330003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.
    Sandulache VC; Ow TJ; Daram SP; Hamilton J; Skinner H; Bell D; Rosenthal DI; Beadle BM; Ang KK; Kies MS; Johnson FM; El-Naggar AK; Myers JN
    Head Neck; 2013 Oct; 35(10):1454-60. PubMed ID: 23018868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Chen MM; Colevas AD; Megwalu U; Divi V
    Oral Oncol; 2018 Sep; 84():71-75. PubMed ID: 30115479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence.
    Bhayani MK; Hutcheson KA; Barringer DA; Lisec A; Alvarez CP; Roberts DB; Lai SY; Lewin JS
    Head Neck; 2013 Nov; 35(11):1634-40. PubMed ID: 23322563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and definitive management of oropharyngeal hemorrhage in patients with squamous cell carcinoma of the oropharynx.
    Araujo AV; Wax MK; Clayburgh DR; Andersen PE; Chandra RA; Li RJ
    Head Neck; 2024 Apr; 46(4):896-904. PubMed ID: 38216834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma.
    Gharzai LA; Li P; Schipper MJ; Yao J; Mayo CS; Wilkie JR; Hawkins PG; Lyden T; Blakely A; Ibrahim M; Schonewolf CA; Shah J; Eisbruch A; Casper K; Mierzwa M
    Oral Oncol; 2020 Dec; 111():104853. PubMed ID: 32805634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
    Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in surgically resectable oropharynx cancer treated with transoral robotic surgery versus definitive chemoradiation.
    Dhanireddy B; Burnett NP; Sanampudi S; Wooten CE; Slezak J; Shelton B; Shelton L; Shearer A; Arnold S; Kudrimoti M; Gal TJ
    Am J Otolaryngol; 2019; 40(5):673-677. PubMed ID: 31201038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.
    Goepfert RP; Lewin JS; Barrow MP; Fuller CD; Lai SY; Song J; Hobbs BP; Gunn GB; Beadle BM; Rosenthal DI; Garden AS; Kies MS; Papadimitrakopoulou VA; Schwartz DL; Hutcheson KA
    Laryngoscope; 2017 Apr; 127(4):842-848. PubMed ID: 27440393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: An institutional experience.
    Wotman M; Ghaly M; Massaro L; Tham T; Seetharamu N; Kamdar D; Frank D; Kraus D; Teckie S
    Am J Otolaryngol; 2019; 40(5):684-690. PubMed ID: 31229365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.